Gastrointestinal Adverse Reactions In clinical trials in adults for weight reduction, 73% of WEGOVY-treated patients and 47% of patients receiving placebo reported gastrointestinal adverse reactions, including severe reactions that were reported more frequently among patients receiving WEGOVY (4.1%) than placebo (0.9%)
The Bottom Line Your body already produces GLP-1, the same hormone pathway targeted by medications like Ozempic, Wegovy, and semaglutide
Importantly, the antidepressant-like property is dose-dependent, with the maximum effect obtained when valsartan is administered at a dose of 40 mg/kg/day (191)
Lowering inflammation can help alleviate some symptoms, such as fatigue and joint pain, and may slow down the progression of autoimmune thyroid damage
[11] As a precautionary measure, individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) are typically excluded from trials